Interestingly, the migratory capacity of CD209+/CD14+ dendritic cells has been shown to be significantly inhibited by a JAK/STAT pathway inhibitor (tofacitinib) used in the treatment of various autoimmune diseases [49]. The gene discussed is SOAT1; the disease is autoimmune disease.